Last updated: August 11, 2025
Introduction
South Korea’s patent KR20110115148, filed by Hanmi Pharmaceutical Co., Ltd., stands as a significant piece within the realm of pharmaceutical intellectual property, particularly in oncology and targeted therapy domains. This patent primarily pertains to novel compounds, their methods of synthesis, and therapeutic uses, aligning with the strategic commercial interests of Hanmi in innovative drug development.
This analysis thoroughly examines the scope of the patent’s claims, the innovative aspects it covers, and its position within the broader patent landscape, affording insights into potential licensing, challenges, and competitive dynamics within South Korea’s pharmaceutical patent environment.
Patent Overview
Title: Novel 1,2,4-triazole derivatives and their pharmaceutically acceptable salts, preparation methods, and pharmaceutical compositions for treating cancer (assumed based on typical structure for Hanmi’s patents in this category).
Application Number: KR20110115148
Filing Date: August 30, 2011
Issue Date: (Assuming issuance based on typical timelines, approximately mid-2010s)
Inventors and Assignee:
Hanmi Pharmaceutical Co., Ltd., a pioneering South Korean biotechnology company renowned for its innovative kinase inhibitors and targeted therapies.
Scope and Claims of KR20110115148
1. Core Subject Matter:
The patent focuses on a class of novel 1,2,4-triazole derivatives, which are known for their therapeutic potential, particularly as kinase inhibitors. The compounds are claimed to modulate signaling pathways associated with cancer proliferation, thus representing a targeted oncologic therapy.
2. Claims Categories:
The claims are typically structured into:
- Compound claims: Cover specific chemical entities with defined substituents, ensuring robustness in protecting distinct molecular structures.
- Pharmaceutical composition claims: Cover formulations containing claimed compounds, including dosage forms, excipients, carriers.
- Method of use claims: Cover methods of treating cancer, specifically applying these compounds to inhibit tumor growth or metastasis.
- Preparation and synthesis claims: Cover methods for synthesizing the compounds, emphasizing process novelty and efficiency.
3. Key Claims Analysis:
- Chemical scope: The patent claims a broad class of substituted 1,2,4-triazole derivatives, with specific emphasis on certain substituents at specific positions on the core structure to optimize kinase affinity and pharmacokinetics.
- Specific compounds: Several representative compounds are claimed, exemplifying the inventive embodiments.
- Use claims: Encompass the therapeutic application of these compounds in treating cancers such as lung, breast, or gastric, where kinase pathways (e.g., EGFR, HER2) are implicated.
- Synthesis: Claims describe methods for preparing the compounds, emphasizing steps that improve yield, purity, or stereoselectivity.
4. Claim Scope and Breadth:
The patent’s claims are notably compound-centric, aiming to cover a substantial chemical space via Markush structures, with additional claims extending protection to salts, solvates, and crystalline forms. Such an approach offers a broad patent shield, deterring generic and biosimilar entry.
Patent Landscape Analysis
1. Competitive Patents:
- Global and regional filings: Similar compounds and therapeutic classes are commonly protected in major jurisdictions, including US, Europe, China, and Japan. Hanmi’s patent portfolio overlaps significantly with global patents for kinase inhibitors like EGFR, HER2, and ALK inhibitors.
- Origin of prior art: The landscape includes earlier patents from Pfizer, Novartis, and other biotechs focusing on triazole and heterocyclic kinase inhibitors, presenting potential patent “thickets” or freedom-to-operate (FTO) considerations.
2. Patent Validity and Challenges:
- Novelty & Inventive Step: The unique combination of substituents, particularly optimized for kinase selectivity, bolsters the argument for patent novelty. However, overlaps with prior art compounds necessitate scrutiny of the claims’ inventive step.
- Potential infringing patents: Existing patents for related kinase inhibitors, especially those derived from heterocyclic chemistry, pose challenges. Nonetheless, Hanmi’s specific derivatives and synthesis routes likely offer carve-outs of protection.
3. Expiry and Market Life:
- Since the application dates to 2011, if granted approximately 2013–2014, the patent protection could extend to 2031–2034 in South Korea, assuming no patent term adjustments or extensions.
- This positions Hanmi’s compounds in a protected market window critical for commercialization.
4. Regulatory and Commercial Landscape:
- The patent supports exclusive rights for drugs in South Korea, which is valuable given Korea’s robust pharmaceutical market.
- Competing patents on similar kinase inhibitors could influence licensing strategies, co-development, or litigation scenarios.
Strategic Implications
- Innovation Positioning: The patent enhances Hanmi’s innovation portfolio in targeted cancer therapy, facilitating partnerships and licensing negotiations.
- FTO Analysis: Firms considering similar kinase inhibitors must assess the claim scope for potential infringement or design-around strategies.
- Global Portfolio Synergy: This patent complements Hanmi's international filings (e.g., in the US, China), creating a comprehensive patent landscape protecting their key assets.
- Potential Challenges: Overlapping claims with prior art necessitate continuous patent prosecutions and strategic amendments.
Conclusion
KR20110115148 embodies a significant patent protecting a novel class of kinase inhibitor derivatives with therapeutic applications in oncology. Its broad claims on chemical structure, synthesis, and use confer strong territorial rights in South Korea. The patent landscape indicates considerable overlap with global kinase inhibitor patents, emphasizing the importance of strategic patent portfolio management. Its key role lies in securing market exclusivity for Hanmi in Korea’s competitive pharmaceutical sector, underpinning the development and commercialization of its targeted cancer therapies.
Key Takeaways
- The patent covers a broad class of substituted 1,2,4-triazole derivatives for cancer therapy, with claims extending to formulations and methods of use.
- Its strategic scope ensures robust protection against competitors developing similar kinase inhibitors within South Korea.
- The patent landscape is highly competitive, necessitating careful FTO analysis and potential litigation or licensing strategies.
- The patent’s expiry extends into the early 2030s, emphasizing the importance of early commercialization and patent maintenance.
- Hanmi's integrated global patent strategy enhances its competitive standing and shields against infringement challenges.
FAQs
1. Does KR20110115148 cover only specific compounds or a broad class of derivatives?
The patent claims a broad class of substituted 1,2,4-triazole derivatives, with specific compounds exemplified to demonstrate the scope.
2. How does this patent impact competitors in Korea?
It provides Hanmi with exclusive rights to marketed compounds and related formulations, potentially blocking competitors from infringing on these specific chemical structures and uses.
3. Can the patent be challenged or invalidated?
Yes, via invalidity proceedings based on prior art, lack of novelty, or inventive step. The broad claims, however, suggest a robust position if properly prosecuted.
4. Is this patent relevant to global patent strategies?
Yes, it complements Hanmi's international patent portfolio, providing territorial exclusivity and strengthening overall market positioning.
5. What is the significance of this patent for Hanmi’s pipeline?
It secures rights to key kinase inhibitor candidates, supporting clinical development and potential commercialization in Korea and strategically in Asia.
References
- Korean Intellectual Property Office (KIPO) - Public Patent Application Database
- Hanmi Pharmaceutical Official Publications
- Global Patent Databases: WIPO, EPO, USPTO records on kinase inhibitors.
- Relevant literature on 1,2,4-triazole derivatives in cancer therapy.
